Wednesday 20 October 2010

Recombumin

The future of formulation is clear!

The world’s first and only, animal-free, commercially available recombinant human albumin, approved for use in the manufacture of human therapeutics.

Used in the manufacture of the FDA and EMEA approved M-M-R™ II childhood vaccine from Merck and Co., Recombumin* is also being evaluated as an excipient, or ingredient, in several other products undergoing clinical development in the US and EU. 

Key benefits

  • Stabilize your product in liquid formulation at room temperature
  • Improve visual appearance of lyophilized product and decrease dissolution time
  • Manufactured to Q7 GMP in FDA, Health Canada and MHRA inspected facilities
  • Extend product bioavailability
  • Half-life extension of peptides.

Application areas

No comments:

Post a Comment